Читать книгу Transfusion Medicine - Jeffrey McCullough - Страница 152

The approach to blood safety during the past 40 years has been very successful but is nearing the end of its effectiveness [118–121]. Addition of new tests and/or screening measures erodes the donor base unnecessarily and is reactive, allowing patients to be harmed before preventive steps are implemented. Several pathogen‐inactivated plasma products and two pathogen‐inactivated platelet products are widely used outside the United States, and one platelet and two plasma products are FDA licensed for domestic use. This technology is reviewed extensively by Prowse [121, 122] and in a Cochrane review [123]. Refer to Chapter 14 for additional information on Pathogen‐reduced blood products.